Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[2] Alapryl in Spain,[3] and Pacinone in Portugal.[4]

Medical uses

Halazepam was used for the treatment of anxiety.[2]

Adverse effects

Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[2]

Pharmacokinetics and pharmacodynamics

Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:[5]

Onset of action Intermediate to slow
Plasma half life 14 hr for parent drug and 30-100 hr for its metabolite
Peak plasma levels 1-3 hr for parent drug and 3-6 hf for its metabolite
Metabolism Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
Excretion Excreted through kidneys
Protein binding 98% bound to plasma protein

Regulatory Information

Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[6]

Commercial production

Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[2]

See also

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ a b c d "halazepam". Drugs.com. Retrieved December 11, 2014.
  3. ^ "Alapryl". Drugs.com. Retrieved December 11, 2014.
  4. ^ "Pacinone". Drugs.com. Retrieved December 11, 2014.
  5. ^ Sellers EM (1998). "Antianxiety agents: benzodiazepine derivatives". In Quitkin FM, et al. (eds.). Current Psychotherapeutic Drugs (2nd ed.). Washington: American Psychiatric Press. p. 166. ISBN 978-0-88048-994-2.
  6. ^ "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Regulations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.


Allikas: https://en.wikipedia.org/wiki/Halazepam
No tags for this post.